Skip to main content
News Archive

MedImmune in £multi million deal to strike cancer

By January 10, 2014May 22nd, 2025No Comments

Medimmune logo

AstraZeneca today announced that Granta Park-based MedImmune, its global biologics research and development arm, has entered into a cancer research collaboration and licensing agreement with Immunocore, an Oxford biotech company.

The approach will be to use the power of the body’s own immune system to find and kill diseased cells, avoiding damage to healthy cells.

{iframe}http://www.cambridge-news.co.uk/Business/Business-News/MedImmune-in-multi-million-deal-to-strike-cancer-20140108105710.htm{/iframe}

Search

You have successfully subscribed to the newsletter

There was an error while trying to send your request. Please try again.

BioHealth Innovation will use the information you provide on this form to be in touch with you and to provide updates and marketing.